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Introduction 
Raman spectroscopy (RS) is a vibrational 
spectroscopic technique that relies on inelastic 
scattering of light by polarizable molecules.  Raman 
scatter occurs when photons of a defined energy 
impinge on an analyte, leading to the emission of 
lower energy photons, which are detected and 
provide information on the biochemical composition 
of cells, tissues and biofluids[1]. The method offers 
chemical detection, analysis and interpretation with 
minimal or no sample preparation as Raman is an 
optical technique[2]. RS has been used to analyze 
biological samples for decades, but with recent 
advances in lasers and fibre optics along with 
improvements in spatial resolution and scan speed it 
is now feasible to implement Raman in a routine 
clinical setting for in vivo disease classification and 
diagnosis[3]. The fundamental belief underpinning 
these developments is that disease-related molecular 
changes in cells, tissues or biofluids can be reliably 
and reproducibly detected by RS and used as 
fingerprints[1]. Importantly, multivariate calibration 
and classification models can be applied to mine large 
spectral datasets in order to obtain quantitative and 
objective diagnoses in a range of diseases[4, 5]. RS 
therefore has the potential to be used for diagnostics, 
prognostics and as a tool for evaluating response to 
treatment. 
Colorectal cancer (CRC) is one of the most prevalent 
cancers in the developed world[6], but is also one of 
the most easily curable if detected at an early-stage[7].  
Genetic mutations cause CRCs and the disease is 
broadly categorized into hereditary and sporadic 
types, which have differing genetic causes[8]. In most 
cases the disease develops slowly and a number of 
CRCs remain asymptomatic for many years prior to 
diagnosis. Fecal occult blood testing is widely used to 
screen for CRC, but although the technique is cheap 
and inexpensive it is error-prone in detecting CRCs[9]. 
Therefore patients with abnormal screening results 
are examined by colonoscopy and CRCs are routinely 
detected by visual inspection of suspicious lesions and 
polyps that are seen during the procedure. Suspicious 
tissues are removed during colonoscopy, stained with 
chemical dyes, and later inspected by a pathologist 
for any sign of cancer. This method can provide a 
basic diagnosis of cancer presence and stage, 
however simple visual inspection provides no 
information on the origin of the disease or disease-
associated genetic markers. This information is 
obtained by analysis of known cancer markers, for 
example genetic mutations must be uncovered using 
next generation sequencing and aberrations at the 
protein level with immunohistochemistry (IHC) 
respectively.   
Two of the most widely used groups of molecular 
markers are carcinoembryonic antigens and 
carbohydrate antigens[9]. The markers have been 
associated with cancer progression and prognosis[10, 
11]. Microsatellite instability has also been linked with 
a large fraction of colorectal cancers and these are 
identified using immunohistochemistry (IHC). IHC is 
widely used in pathology to detect disease-related 
tissue antigens via antigen-antibody binding. In colon 
cancers, the technique is used to detect MLH1 and 
MSH2, which are key proteins involved in DNA 
mismatch repair and a loss of these proteins is 
indicative of microsatellite instability[9]. IHC also plays 
an important role in the detection of mucinous 
tumors in colon, with most advanced colorectal 
tumors abnormally secreting mucins, linking 
mucinous tumors with poor survival rates[12]. 
However, these types of genetic analyses are not 
routinely performed due to their cost. Furthermore, 
IHC is a very powerful tool in CRC diagnosis because it 
provides pathologists with additional (spatial) 
morphological information which can be used in 
phenotyping tumors. IHC relies on the ability of 
target-specific antibodies to bind antigens on tissue 
sections. For detection purposes the antibody probes 
are commonly linked to reporter molecules.  These 
alert the pathologist to the antibody binding locations 
on the tissue sample by their direct UV or visible 
emission/absorption spectra or capacity to deposit 
easily visible stains (chromogens).  Although 
extremely useful and well established in the field, IHC 
methods suffer a number of limitations when applied 
to tissue specimens. Firstly, the technique relies upon 
the availability of an antibody that specifically binds 
to an antigen of known interest. Once the appropriate 
antibody has been selected, staining is only reliable 
when samples are promptly fixed and reliably 
processed in order to maintain antigen viability[13]. 
The size of the tissue section available for staining is 
also of concern as small specimens are unsuitable for 
staining as the number of tumor cells may be below 
the detection limit and there may also be insufficient 
material available to confirm a positive result[9]. 
Staining is normally completed over a period of hours 
and protocols commonly implement a number of 
washing, blocking and incubation steps. The complex, 
multi-step nature of IHC staining also means that the 
reliability of results is governed by the experience of 
the operator performing staining, features of any 
automation used and quality of the antibodies; all of 
these features may contribute to variance in the data 
and create significant bias[13]. Furthermore, since 
markers need to be pre-selected and demonstrated 
to correlate with disease the technique is not suitable 
for identifying general abnormalities. 
We are focusing on FFPE tissue blocks since these are 
the standard sample format utilized by pathology 
departments for IHC and other diagnostic tests. When 
working with FFPE issues, insufficient paraffin 
removal can lead to a number of known issues in both 
Raman and IHC. Firstly, paraffin peaks appear across 
the biological spectral region, showing distinctive 
Raman contributions around 1063 cm-1, 1133 
cm-1, 1296 cm-1, and 1441 cm-1[14]. Peaks in these 
regions can obscure a multitude of tissue peaks, 
negatively impacting feature detection[15]. Paraffin 
not only physically blocks epitopes on the tissue 
surface, preventing antibody binding, but it can also 
trap excess chromogens, giving a false positive or high 
background signal[16]. It is therefore essential to 
implement thorough and reproducible 
deparafination procedures during tissue processing in 
order to minimize artifacts caused by paraffin 
contribution during analysis.  
RS has been applied to study tissue and cells for 
several decades and has proven that tissue, cell and 
disease-specific spectral signatures are attainable. 
Spectra are generated using Raman scatter from 
components of the genome, proteome and 
metabolome and are displayed as collections of 
overlapping peaks, which can be mined for the 
molecular information they contain. The ability to 
collect all of this data simultaneously, in a single 
spectrum, means that abnormalities can be detected 
rapidly through spectral differences.  For clinical 
application, spectral changes must be correctly 
assigned to the disease under investigation and this is 
routinely accomplished through classification 
algorithms. However, one major drawback to this 
methodology is the current failure of spectroscopists 
to validate their algorithms by reference to proven 
and accepted detection methods and therefore 
adoption of RS by clinicians has proved problematic. 
To validate the capabilities of RS to detect 
pathological changes here we correlate spectral 
features with clinically validated antibody localization 
and show that RS has the potential to, at least, 
complement current IHC methods in the CRC 
pathology workflow. Novel studies using surface 
enhanced RS alongside conventional IHC methods are 
now being implemented. Deemed immuno-RS, the 
method employs surface-enhanced Raman scattering 
from an immuno-Raman label in order to selectively 
detect disease-specific antigens with high sensitivity. 
The protocol has been previously described for PSA 
detection in prostate tissue with promising initial 
results[17]. Additionally, Raman microscopy has more 
recently been compared against IHC data in 
comparing EGFR mutation status in lung 
adenocarcinoma[18]. The study correlated IHC-
associated molecular changes with Raman spectral 
data and built an algorithm capable of diagnosing 
E19del and L858R mutations with an accuracy of 
87.8%. RS could overcome a number of current 
limitations in IHC workflows as it is capable of 
providing simultaneous detection of multiple 
antigens and their spatial distributions in the same 
tissue specimen, removing the need for multiple 
biopsies and antibody panels. The technique is also 
label-free and does not require expensive antibodies 
and dyes to detect antigens like in conventional IHC, 
reducing the cost of analysis.  
These studies have been made possible through 
advances in instrumentation and substrate 
development. Recent substrate developments have 
highlighted stainless steel as suitable, low-cost 
material for tissue analysis, substantially reducing the 
costs associated with Raman analysis of tissue[19]. 
Newly characterized substrates also exhibit improved 
signal to noise ratios over commonly used and 
expensive calcium fluoride, indicating that tissue 
spectra can be obtained at greater speeds [20]. 
Reduction in mapping costs and improvements in 
mapping speed now means that RS has reached the 
stage where it has the potential to be integrated into 
the pathology workflow. RS is objective and offers a 
very reliable diagnosis as it provides a biochemical 
fingerprint of the tissue under investigation and does 
not rely upon subjective assessment. Previous studies 
have combined RS with basic hematoxylin and eosin 
(H&E) staining and white light microscopy images [21-
23], while this paper is the first of its kind to investigate 
the tissue morphological information that can be 
obtained in a direct comparison between RS and IHC. 
Results clearly show the co-localization of spectral 
signatures with IHC staining and demonstrate the 
multiplexing capabilities of RS. 
 
Materials and Methods 
 
Tissue Preparation 
Formalin fixed paraffin embedded human colon 
tissue blocks were obtained from the UCL Biobank 
(REC 15/YH/0311). For each tissue block 8 µm tissue 
sections were prepared for RS on stainless steel 
slides, described previously by our group[19]. All 
samples for RS were deparaffinated with xylene with 
four, five-minute baths prior to rehydration and 
downstream analysis. Dewaxed samples were stored 
at room temperature and were Raman-mapped 
within 24 hours of rehydration.  
For each sample prepared for RS contiguous 3 µm 
tissue sections were also cut for IHC and H&E staining. 
H&E staining was carried out using the appropriate 
standard protocol and IHC staining, deparaffination 
and antigen retrieval was performed on a Leica Bond 
III auto-immunostaining platform, using Leica Bond 
Polymer Refine Detection (Leica DS9800) with DAB 
chromogen. The fully-automated system was run 
under optimal conditions for each antibody, as 
determined by positive controls. Primary antibodies 
were applied for 15 minutes at room temperature. Ki-
67 antibody (Dako mouse clone MIB-1, M7240) was 
used at a dilution of 1/120 and epitope retrieval 
performed in Leica ER2 solution for 20 minutes at 
99°C. Desmin antibody (Leica mouse clone DE-R-11, 
PA0032) was used as per manufacturer’s protocol and 
antigen retrieval performed in Leica ER2 solution for 
20 minutes at 99°C. Anti-MUC2 (Leica mouse clone 
Ccp58, NCL-MUC-2) was applied at a dilution of 1/200 
and epitopes retrieved in Leica ER2 solution for 30 
minutes at 99°C. Collagen III antibody (GeneTex 
mouse clone FH-7A, GTX26310) was applied at a 
dilution of 1/500 and epitope retrieval was carried 
out in Leica ER1 solution for 30 minutes at 99°C. 
Finally, anti-CD20 (Dako mouse clone L26, M0755) 
staining was performed at a dilution of 1/100 and 
epitope retrieval performed in ER1 solution for 20 
minutes, also at 99°C. 
 
Raman Measurement 
A Renishaw RA800 series benchtop Raman system 
configured for pathology use was used for all 
measurements. The instrument is configured with a 
1500 lines per mm diffraction grating, 785 nm laser 
excitation wavelength, a 50x, NA 0.75 objective and a 
motorized XYZ stage. The system is capable of 
imaging in transmitted and reflected white light mode 
for sample identification on both transparent and 
opaque substrates. StreamLine™ Raman imaging, a 
fast mapping method, was used for data collection. 
The spectral resolution was 2.5 cm-1 with a range of 
150-2100 cm-1. Fully-automated spectral alignment 
and calibration routines were in operation to ensure 
data reproducibility. Spectral collection was 
controlled by WiRE 4.0 software (Renishaw PLC). 
Raman maps were collected at an acquisition time of 
0.3 seconds per pixel at 1.05 µm spatial resolution. 
Spectra were collected with a laser power of 230 mW 
measured at the sample. 
Pre-processing of raw spectra included cosmic ray 
removal and baseline correction using WiRE 4.0. 
Principal component analysis (PCA), also performed in 
WiRE 4.0 software, was then used for spectral data 
reduction and visualization. PCA was applied to the 
entire spectral region and spectra were mean 
centered and normalized by standard normal variate 
normalization. Spectral data was reduced to ten key 
components that explained the majority of the 
variance in the data. These components were used to 
plot pseudo-color images, which were created by 
applying a color weighting to the loadings of principal 
components from the spectral datasets. The resulting 
image displays the relative intensity of each 
component and its spatial distribution across the 
mapped region, and therefore in the sampled tissue.   
 
Results and Discussion 
Normal colon sections with easily distinguishable 
tissue morphology were selected for analysis in this 
proof of concept study (Figure 1). Areas covering 
longitudinal crypt sections were selected for Raman 
mapping in contiguous sections since these contained 
discernable tissue features that could be easily 
compared to Raman data in the initial stages. The 
outermost structure of the colon consists of the 
lumen, which forms the tubular space inside the 
colon. Next, the mucosal layers makeup the inner 
lining of the colonic tissue and consists of the 
epithelium, a layer of connective tissue called the 
lamina propria and a layer of thin muscle, the 
muscularis mucosa. The colonic crypts are found 
within the mucosal layer in normal, healthy colon and 
contain a base of stem cells and are also lined with 
mucus secreting cells, amongst other cell types. 
Tissue maps were generated using Raman 
spectroscopy and corresponding tissue sections 
stained with the antibody panel; anti-Ki-67, anti-
desmin and anti-MUC2. Antibody stained tissue 
appears brown due to the DAB reaction and cell nuclei 
are counterstained blue/violet with hematoxylin, 
which binds to lysine residues localized to nuclear 
histones. 
Raman spectroscopy provides a biological 
‘fingerprint’ of the specimen under investigation 
between 450 – 2000 cm-1 and specific regions of the 
spectrum can be used to confirm the presence of 
various tissue components. Most notably, bond 
vibrations attributed to proteins at 1500 –1700 cm-1, 
carbohydrates at 470 –1200 cm-1 and DNA at 980, 
1080 and 1240 cm−1 are all present in the spectrum[24, 
25]. Additionally, higher frequency modes due to lipid-
associated bond vibrations can be found at 2700 – 
3500 cm-1 [25]. 
 
PCA is an unsupervised, multivariate analysis 
technique that reduces the variance of the spectral 
dataset into a set of components that explain the 
variance within the data set. Individual components 
can be more easily visualised in space and represent 
a combination of loadings derived from a mixture of 
spectral features that best describe each component. 
The majority of the variance in the spectral dataset is 
explained by the first component, and the fraction 
explained then decreases sequentially with each 
subsequent component. For us the first three 
components explained the majority of the variance in 
the dataset and were deemed most histologically 
relevant. 
 
 
Figure 1 H&E stained longitudinal section of a normal colon 
tissue sample outlining major tissue structures. The colonic 
lumen (L) is visible in the bottom left and a whole colonic 
crypt, from crypt opening (CO) to crypt base (CB), through 
crypt lumen (CL), is identified between arrows. The lamina 
propria (LP), a layer of connective tissue surrounding the 
crypts can also be identified. The submucosa (S) is 
orientated to the top right corner of the image and connects 
the mucosa to the muscularis propria.  The muscularis 
mucosa (MM) is a thin layer of muscle separating crypt 
bases and the submucosa. Blood vessel (BV).      
Anti-desmin binds to desmin, a filament protein 
localized to muscle fibers that is responsible for 
connecting myofibrils to one another and to the 
plasma membrane. We observe intense anti-desmin 
staining localized to the muscularis mucosae, a thin 
layer of muscle that can be seen running along the 
crypt base. Staining of the plasma membrane on 
stromal cells, likely pericytes[26], outlining the 
boundaries of crypt structures can also be seen[27]. 
Fundamentally, the corresponding Raman map 
created using the PC1 loading shows good correlation 
to the staining density obtained with anti-desman 
IHC. Again, the muscularis mucosae has the highest 
Raman signal and signals outlining the plasma 
membranes of individual cells are also visible. The 
major spectral contributions used to generate the PC1 
red pseudo-color image can be attributed to amino 
acid scatter, which have easily distinguishable 
spectra, even in complex biological samples[28]. 
Intense peaks corresponding to proline at 852 cm-1, 
phenylalanine at 1004 cm-1 and the CH2 bending 
mode of proteins at 1449 cm-1 all indicate that protein 
scatter is the major contributor to PC1[29].  
Anti-Ki67 stains a large nuclear protein that is 
expressed during all active phases of the cell cycle and 
is an established marker of cell proliferation. We 
would therefore expect the distribution of this stain 
to be localized to cell nuclei and to be of highest 
intensity towards the crypt base as this is where the 
cells are documented to be proliferating most rapidly. 
Figures 2 and 3 verifies this observation; the most 
intense anti-Ki67 staining is localized to crypt bases, 
with minor staining also found along the epithelium 
where cells are also dividing. The pseudo-color Raman 
comparison (created from the PC2 loading in the 
Principal Component Analysis) arises from DNA/RNA 
signals. Peaks characteristic of DNA have previously 
been assigned at 782 cm-1, 1100 cm-1, 1335 cm-1, 1573 
cm-1 and 1662 cm-1 [29] and corresponding peaks in the 
loadings of PC2 could be found at 780 cm-1 and 1105 
cm-1 in our spectra. Even though the major peak in the 
loading identified around 556 cm-1 could not be 
assigned to DNA, the IHC/RS comparison for the Ki67 
marker shows good correlation with DNA since the 
greatest scattering intensity is also mapped to crypt 
bases, where cells are actively proliferating. The same 
image also shows nucleotide scatter along crypt 
epithelium where cells are also growing, although to 
a lesser extent than at the crypt base. Variation in 
cellular DNA content is associated with different 
phases of the cell cycle[30]. RS is capable of identifying 
nucleotide signals and a major component identified 
in the spectral dataset could be related to nucleotide 
scatter; it is this component that was used to 
generate the pseudo-color (green) image for 
comparison against the Ki67 stain.  
 
MUC2 is the major mucin localized to the colon, more 
specifically to colonic crypts and the lumen. It is likely 
that some mucus remains trapped within the lumen 
of the crypt structures and within goblet cells 
following sample processing. Therefore, anti-MUC2 
was used to check for the presence of the 
glycoprotein. It is useful to be able to identify the 
localization of mucins in different pathologies since 
abnormal expression of these highly-glycosylated 
proteins can signal abnormalities. As expected, the 
antibody intensely stained the lumen of colonic crypts 
and the mucin secretory cells that line them. Since 
mucins are highly decorated with oligosaccharides, 
the major spectral component used to explore the 
distribution of mucins was based on glycan scatter in 
the tissue spectra. The blue distribution in the 
pseudo-color RS image (PC3 loading) also indicates 
the presence of mucin in the secretory cells lining the 
crypt epithelium and in the crypt lumen. Alongside 
several protein peaks identified in the loadings of PC3, 
a peak at 440 cm-1 and a considerable scatter in the 
low wavenumber region is seen to dominate PC3. 
Raman scatter in the low wavenumber region (450 – 
650 cm-1) can be attributed to δ(C-O-C) found in 
glycosidic linkages of carbohydrates[31], which are 
found attached to mucins. Furthermore, since it is 
known that mucins are decorated with sulfate 
groups and that they form disulfide bond stabilized 
networks via cysteine resides, then S-S stretching 
modes arising at 498 cm-1, 512 cm-1 and 529 cm-1[32] 
are most likely contributing to the loadings on PC3. 
Figure 2 Alternating Raman maps (left) and IHC images (right) of colon section showing crypt structures. Red Raman map indicates 
the distribution of muscle fibers and is correlated to anti-desmin, a muscle-specific antibody. Green Raman map highlights the 
distribution of DNA and is correlated to anti-Ki67 staining for proliferating cells. The blue Raman map shows the distribution of 
mucin glycoproteins in colonic crypts and this correlates to anti-muc6 staining in the IHC image. Scale bar is 50 µM. Right hand 
panels display the loadings of the first three principal components identified by PCA with major peaks labelled. Percentage 
variance explained by individual components: PC1 = 40.0; PC2 = 21.5; PC3 = 5.4. 
 
 
 
 
 Figure 3 Alternating Raman maps (left) and IHC images (right) of colon section showing crypt structures. Red Raman map indicates 
the distribution of muscle fibers and is correlated to anti-desmin, a muscle-specific antibody. Green Raman map highlights the 
distribution of DNA and is correlated to anti-Ki67 staining for proliferating cells. The blue Raman map shows the distribution of 
mucin glycoproteins in colonic crypts and this correlates to anti-muc6 staining in the IHC image. Scale bar is 50 µM. Right hand 
panels display the loadings of the first three principal components identified by PCA with major peaks labelled. Percentage 
variance explained by individual components: PC1 = 61.7; PC2 = 7.3; PC3 = 3.6. 
 
 
 
 
There is good correlation between the spatial 
distributions of components in both tissue specimens 
studied. This was to be expected since the first set of 
components are most likely to map to protein and 
DNA, making these molecular species particularly 
easy to discriminate by PCA[33]. Although the 
distribution of protein and DNA are easily identified 
via this method, it is likely that other components that 
scatter less intensely will require more sophisticated 
multivariate analysis methods in order to identify 
their presence and distribution in relation to IHC 
markers. Furthermore, paraffin retention can 
contaminate Raman spectra across the whole 
biological region, masking peaks of interest and 
detrimentally contributing to PC loadings, particularly 
those associated with discriminating lipids[29, 33]. It is 
important that future studies implement vigorous 
methods to remove paraffin from sections prior to 
analysis so that paraffin signals do not interfere with 
the identification of low abundance species or 
changes in lipids in samples. 
To highlight the capabilities of Raman in multiplexing, 
we mapped the distributions of multiple components 
onto a single tissue map. The first five components 
from figure 2 were superimposed onto figure 4, with 
additional components that localized to lipids and 
vasculature (identified by characteristic lipid-
associated Raman scatter attributed to C=C stretch at 
1654 cm-1 [34] in spectral loadings). In the multiplexed, 
pseudo-color image, individually colored components 
clearly indicate the distributions of various 
morphological features and tissue and cellular 
subtypes and these can all be identified from spectra 
collected during a single experimental run. The 
distribution of muscle tissue, DNA, mucus 
glycoproteins and lipids can all be seen and there is an 
obvious greater wealth of information in the Raman 
 
 
Figure 4 Raman false colour map (left) compared alongside a standard H&E stained section that reveals only cytoplasmic and 
nuclear distributions (right). Raman map shows several biochemical components on same section with each color representing 
the spatial distribution of a specific biochemical component, ranging from DNA (green) to muscle fibers (red), lipids (yellow) and 
mucin glycoproteins (blue) as detailed in Figure 2. Scale bar is 50 µM. 
map, at least comparable to that achievable with 
multi-antigen IHC compared to the corresponding 
conventional H&E section, which provides only basic 
morphological detail regarding the localization of cell  
nuclei and cytoplasmic regions. The colonic crypts can 
be easily visualized in the H&E stained section, but 
there is no indication of mucus presence and 
vasculature is more difficult to distinguish.     
On the multiplexed image, as expected, PCA was able 
to distinguish musculature from vascular and 
connective tissue since muscle fibers are 
predominantly comprised of actin and myosin 
proteins. Both actin and myosin possess secondary 
structures rich in alpha helices, which give 
characteristic Raman scatter, and these are dissimilar 
to the spectral patterns obtained from collagen, 
which contains high concentrations of glycine in an 
ordered type-2 helix, hydroxyproline (an amino acid 
rare in other proteins) and a triple helical structure. 
The presence of blood vessels can be distinguished, 
albeit at low contrast, in the H&E stained section, 
however the yellow component attributed to lipids in 
the pseudo-color image cannot be seen. The co-
localization of Ki-67 staining and DNA signal obtained 
using RS to cells lining the colonic crypts was also 
anticipated. Previous work has identified that 
proliferative cells have distinct Raman spectra based 
on the conformation of DNA during various phases of 
the cell cycle. Since the most active, proliferating cells 
are found adjacent to the crypt base (where the 
colonic stem cells reside) and lining the colonic 
epithelium, we would expect an overlap of signals in 
these tissue regions. All cell nuclei can be easily 
distinguished in the H&E image since DNA is densely 
stained violet with hematoxylin. There is good 
correlation between the well-established 
hematoxylin stain for DNA and the DNA Raman 
scatter, which indicates the reliability of the Raman 
signal; strong Raman and dye intensities can be seen 
in crypt bases and along the epithelium lining the 
crypts. Importantly all of these individual components 
have been identified in a single Raman map, using one 
tissue section, proving the multiplexing capabilities of 
RS and directly correlating them to the “ground truth” 
of known IHC and H&E markers. Routinely using RS in 
this manner would minimize the usage of expensive 
antibodies and reduce the number of tissue sections 
required for pathologists to reach a diagnosis, since 
multiple components could be identified in a single 
piece of tissue. Multiplexing would also save time and 
reduce the burden on healthcare staff. The non-
destructive nature of RS also offers the possibility of 
returning the sample to the conventional 
downstream analysis pathway and investigation with 
conventional methods after the tissue has been 
mapped, which is not possible following IHC or H&E 
staining. 
Conclusion 
This proof-of-concept study has demonstrated that 
RS is capable of providing complimentary information 
to IHC for anatomical regions based on tissue-
subtyping. The capabilities of RS to detect chemical 
signatures and to provide predictive models of 
disease using these signatures is already well 
documented. However, previous studies of this 
kind are rarely confirmed by secondary methods, 
whereas this study validates the use of RS in the 
detection of cell and tissue subtyping since the 
correct tissue signals could be mapped to 
clinically validated IHC markers. We show that 
mucins can be easily distinguished due to their 
rich glycosylation, nuclear regions by their DNA 
content and various other tissue types can be 
identified based on differences in amino acid 
content and structural conformation, as is the 
case with muscle fibers and collagen found in 
connective tissue. There is a vast and growing 
catalogue of non-validated RS tissue signatures 
already reported in the literature and, like our 
limited dataset, these should also be verified 
using complementary analytical methods, such 
as MALDI imaging and IHC. Without this link to 
the ground truth established by IHC or other 
molecular techniques the assignment of spectral 
signatures to discrete tissue and cellular 
subtypes through subjective inspection alone 
will remain speculative and loosely correlated. 
Future studies should also include spectra and 
corresponding markers from cell lines, in order to 
confirm the identification of cell type by RS. 
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